![D. Ackermann](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
D. Ackermann
Oprichter bij
Presidio Medical, Inc.
Profiel
D.
Michael Ackermann was the founder of Tangible Science, Inc. (founded 2011), Oculeve, Inc. (founded 2012) where the title held was President & Chief Executive Officer from 2012 to 2015, Oyster Point Pharma, Inc. (founded 2015) where the title held was Chairman from 2017 to 2020, Presidio Medical, Inc. (founded 2017) where the title held was Director, and Tarsus Pharmaceuticals, Inc. (founded 2017) where the title held was Chairman from 2017 to 2022.
Current jobs include Chief Executive Officer, CFO & Secretary at Osanni Bio, Inc., Director-Biotechnology at Stanford Byers Center for Biodesign, and Advisor at Vensana Capital Management LLC since 2019.
Former job includes Vice President-Neurostimulation at Allergan, Inc. from 2015 to 2017.
Education includes undergraduate degree from Vanderbilt University and graduate and doctorate degrees from Case Western Reserve University.
Actieve functies van D. Ackermann
| Bedrijven | Functie | Begin |
|---|---|---|
Presidio Medical, Inc.
 Presidio Medical, Inc. Medical SpecialtiesHealth Technology Develops neuromodulation platform to establish a class of therapeutic medical devices | Oprichter | 01-01-2017 |
Stanford Byers Center for Biodesign
 Stanford Byers Center for Biodesign Miscellaneous Commercial ServicesCommercial Services Engages in training of health technology innovators | Corporate Officer/Principal | - |
Vensana Capital Management LLC
 Vensana Capital Management LLC Investment ManagersFinance Vensana Capital invests in companies located across the globe, primarily in the United States. The firm focuses on companies operating in the field medical technology sector such as medical devices, life science tools & diagnostics, and data science & tech-enabled solutions. It provides financing for early and growth stage capital requirements with an investment size of USD 15 - 50 million. | Consultant / Adviseur | 01-10-2019 |
Eerdere bekende functies van D. Ackermann
| Bedrijven | Functie | Einde |
|---|---|---|
| TARSUS PHARMACEUTICALS, INC. | Oprichter | 02-12-2022 |
| OYSR POIN | Oprichter | 08-10-2020 |
| ALLERGAN, INC. | Corporate Officer/Principal | 01-06-2017 |
Oculeve, Inc.
 Oculeve, Inc. Medical SpecialtiesHealth Technology Develops devices for dry eye disease treatment | Algemeen Directeur | 11-08-2015 |
Tangible Science, Inc.
 Tangible Science, Inc. Medical SpecialtiesHealth Technology Develops a novel polymer based coating technology for use in contact lenses to treat dry eye disease | Oprichter | - |
Opleiding van D. Ackermann
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
65
Eerstegraads connecties
10
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 10 |
|---|---|
Allergan, Inc.
 Allergan, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Oculeve, Inc.
Oculeve, Inc. Medical SpecialtiesHealth Technology Develops devices for dry eye disease treatment | Health Technology |
Vanderbilt University
 Vanderbilt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Case Western Reserve University
 Case Western Reserve University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tangible Science, Inc.
Tangible Science, Inc. Medical SpecialtiesHealth Technology Develops a novel polymer based coating technology for use in contact lenses to treat dry eye disease | Health Technology |
Oyster Point Pharma, Inc.
 Oyster Point Pharma, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company that develops and commercializes pharmaceutical therapies to treat ocular surface diseases | Health Technology |
Vensana Capital Management LLC
Vensana Capital Management LLC Investment ManagersFinance Vensana Capital invests in companies located across the globe, primarily in the United States. The firm focuses on companies operating in the field medical technology sector such as medical devices, life science tools & diagnostics, and data science & tech-enabled solutions. It provides financing for early and growth stage capital requirements with an investment size of USD 15 - 50 million. | Finance |
Tarsus Pharmaceuticals, Inc.
 Tarsus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company which develops and commercializes therapeutic drugs for blepharitis | Health Technology |
Presidio Medical, Inc.
Presidio Medical, Inc. Medical SpecialtiesHealth Technology Develops neuromodulation platform to establish a class of therapeutic medical devices | Health Technology |
Stanford Byers Center for Biodesign
Stanford Byers Center for Biodesign Miscellaneous Commercial ServicesCommercial Services Engages in training of health technology innovators | Commercial Services |
